Biocon

Through this in-licensing deal, Biocon Biologics has expanded its current therapeutic basket of biosimilars going beyond diabetes,…

Insulin glargine is indicated for the treatment of type 1 diabetes mellitus in adults, adolescents and children aged six years and…

The facility is expected to be operational in a few months post qualification and will house over 250 scientists Biocon said…

Under the terms of the agreement, Biocon will be responsible for the development, manufacturing and supply of the products…

As per the USFDA, a Complete Response Letter (CRL) is sent to an applicant if the agency determines that it will not approve the…

The approval expands Biocon’s capacities, with new large scale devices facility coming up to speed to serve growing needs of…

Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme…

EBITDA up 51 per cent at Rs 462 crores, net profit (excluding exceptional item) up 86 per cent at Rs 223 crores, small molecules…

The drugs include those used for treating conditions like diabetes, inflammation and chronic hepatitis C, among others

The USD 5 million contribution would be contributed to the Research Hub, currently under construction on the Western Infirmary…